Karyopharm Therapeutics (KPTI) Retained Earnings (2012 - 2026)
Karyopharm Therapeutics' (KPTI) quarterly Retained Earnings came in at -$1.8 billion in Q4 2025, down 15.13% YoY from -$2.1 billion in Q4 2024, and down 8.61% on a QoQ basis from -$1.7 billion in Q3 2025.
Karyopharm Therapeutics (KPTI) Retained Earnings (2012 - 2026) Analysis & Trends
Karyopharm Therapeutics (KPTI) has 14 years of Retained Earnings data on file, last reported at -$1.8 billion in Q4 2025.
- Quarterly Retained Earnings fell 15.13% year-over-year to -$1.8 billion in Q4 2025, while the trailing twelve-month figure through Dec 2025 was -$1.8 billion (down 15.13% YoY) and the FY2025 annual result came in at -$1.8 billion, down 15.13% from the prior year.
- Retained Earnings declined to -$1.8 billion in Q4 2025, from -$1.7 billion in the prior quarter.
- In the past five years, Retained Earnings ranged from a high of $372000.0 in Q3 2021 to a low of -$1.8 billion in Q4 2025.
- A 5-year average of -$659.1 million and a median of -$767500.0 in 2022 frame the typical range for Retained Earnings.
- Annual changes were most pronounced in 2021 — Retained Earnings soared 100.03% — and 2024, when it plunged 970993.17%.
- Tracing KPTI's Retained Earnings over 5 years: stood at -$1.2 billion in 2021, then jumped by 99.95% to -$638000.0 in 2022, then surged by 74.76% to -$161000.0 in 2023, then sank by 970993.17% to -$1.6 billion in 2024, then decreased by 15.13% to -$1.8 billion in 2025.
- The last three Retained Earnings figures came in at -$1.8 billion (Q4 2025), -$1.7 billion (Q3 2025), and -$1.6 billion (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Retained Earnings (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 15.69 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 37.62 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 558.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 5.10 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 13.05 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | -6.33 Bn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 20.91 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 6.57 Bn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 4.38 Bn |
| 10 | Karyopharm Therapeutics | 56.72 Mn | 56.72 Mn | 32.35 Mn | -1.85 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -1.85 Bn |
| Dec 31, 2025 | -1.80 Bn |
| Sep 30, 2025 | -1.66 Bn |
| Jun 30, 2025 | -1.60 Bn |
| Mar 31, 2025 | -321,000.00 |
| Dec 31, 2024 | -1.56 Bn |
| Sep 30, 2024 | -222,000.00 |
| Jun 30, 2024 | -1.50 Bn |
| Mar 31, 2024 | -518,000.00 |
| Dec 31, 2023 | -161,000.00 |
| Sep 30, 2023 | -1.45 Bn |
| Jun 30, 2023 | -783,000.00 |
| Mar 31, 2023 | -419,000.00 |
| Dec 31, 2022 | -638,000.00 |
| Sep 30, 2022 | -752,000.00 |
| Jun 30, 2022 | -1.27 Bn |
| Mar 31, 2022 | 87,000.00 |
| Dec 31, 2021 | -1.18 Bn |
| Sep 30, 2021 | 372,000.00 |
| Jun 30, 2021 | -1.17 Bn |